06:39 AM EDT, 09/02/2025 (MT Newswires) -- Upstream Bio ( UPB ) said Tuesday that a phase 2 trial of verekitug to treat chronic rhinosinusitis with nasal polyps met its primary endpoint and key secondary endpoints.

Verekitug dosed 100 milligrams every 12 weeks showed "statistically significant and clinically meaningful" reductions in both endoscopic nasal polyp score and nasal congestion score over the 24-week treatment period, the company said.

Results also showed a generally well tolerated safety profile consistent with previous studies. The treatment also led to a "significant" reduction in the need for surgery or systemic corticosteroids, Upstream Bio ( UPB ) said.